Amgen Announces the European Medicines Agency Acceptance of Kyprolis® (carfilzomib) Marketing Authorization Application for the Treatement of Relapsed Multiple Myeloma

Amgen and its subsidiary Onyx Pharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The MAA has been granted accelerated assessment by the EMA.
Source: International Myeloma Foundation - Category: Hematology Source Type: news